title: Effects of suramin on anastomotic colon tumors in a rat model.
abstract: BACKGROUND
  The development of antiangiogenic drugs offers new promise in the treatment of malignancy. Suramin has been reported to inhibit tumor growth by blocking angiogenesis and has been used in clinical trials. The aim of the present study was to examine the effects of suramin on colonic anastomotic tumors in the rat.
  
  
  METHODS
  (a) Colonic anastomotic tumor was induced in 120 WAG/RIJ rats. Half of the animals were given 100 mg/kg of suramin intraperitoneally at the time of tumor induction. Rats were sacrificed after 2, 4 and 8 weeks; tumor take and tumor weight were evaluated. (b) The number of red blood cell clusters per x 400 field was counted in each tumor. (c) A lymphocyte transformation test was performed in four groups of animals, 2 weeks before and 2 weeks after tumor implantation and/or suramin administration.
  
  
  RESULTS
  (a) A significant enhancement of tumor growth was observed in the suramin-treated animals. (b) This was accompanied by a significant increase in functional blood vessels. (c) Suramin-treated rats had markedly decreased lymphocyte stimulation, pointing to a possible immunosuppressive effect.
  
  
  CONCLUSIONS
  The growth of an anastomotic colon tumor is rather enhanced by a single intraperitoneal administration of 100 mg/kg suramin in the rat, possibly by an unexpected immunosuppressive effect.
authors.affiliation: Laboratory for Experimental Surgery and Department of Immunology, 'Medisch Instituut Sint Augustinus', Antwerp, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Lauwers
authors.forename: G
authors.initials: G
authors.lastname: Hubens
authors.forename: J
authors.initials: J
authors.lastname: Hendriks
authors.forename: P
authors.initials: P
authors.lastname: Vermeulen
authors.forename: A
authors.initials: A
authors.lastname: Schuerwegh
authors.forename: W J
authors.initials: WJ
authors.lastname: Stevens
authors.forename: L S
authors.initials: LS
authors.lastname: De Clerck
authors.forename: L
authors.initials: L
authors.lastname: Dirix
authors.forename: E
authors.initials: E
authors.lastname: Van Marck
authors.forename: A
authors.initials: A
authors.lastname: Hubens
authors.forename: E
authors.initials: E
authors.lastname: Eyskens
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000714:Anastomosis, Surgical / Q000009:adverse effects; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D003106:Colon / Q000473:pathology / Q000601:surgery*; D003110:Colonic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D011919:Rats, Inbred Strains; D013498:Suramin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D013498:Suramin